Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v25-EN Version v3-EN
Language English English
Date Updated 2023-04-28 2022-09-23
Drug Identification Number 02396661 02396661
Brand name TEVA-RIZATRIPTAN ODT TEVA-RIZATRIPTAN ODT
Common or Proper name TEVA-RIZATRIPTAN OD TEVA-RIZATRIPTAN OD
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients RIZATRIPTAN RIZATRIPTAN
Strength(s) 5MG 5MG
Dosage form(s) TABLET (ORALLY DISINTEGRATING) TABLET (ORALLY DISINTEGRATING)
Route of administration ORAL ORAL ORAL ORAL
Packaging size 6 6
ATC code N02CC N02CC
ATC description ANTIMIGRAINE PREPARATIONS ANTIMIGRAINE PREPARATIONS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-09-22 2022-09-22
Estimated end date 2023-03-10 2022-11-10
Actual end date 2023-04-27
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments